8-K

KORRO BIO, INC.

Date: November 14, 2023

/s/ Ram Aiyar

President and Chief Executive Officer

0001193125-23-277147.txt : 20231114 0001193125-23-277147.hdr.sgml : 20231114 20231114163156 ACCESSION NUMBER: 0001193125-23-277147 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Korro Bio, Inc. CENTRAL INDEX KEY: 0001703647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472324450 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39062 FILM NUMBER: 231407069 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE. BUILDING 600-700 STREET 2: SUITE 6-401 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-468-1900 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE. BUILDING 600-700 STREET 2: SUITE 6-401 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Frequency Therapeutics, Inc. DATE OF NAME CHANGE: 20170412 8-K 1 d416540d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2023

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39062

47-2324450

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification

No.)


One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA		02139
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 468-1999

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

KRRO

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 10, 2023, we entered into a new employment agreement with Ram Aiyar, Ph.D., our President and Chief Executive Officer and principal executive officer, and on November 8, 2023, we entered into a new employment agreement with Vineet Agarwal, our Treasurer and Chief Financial Officer and principal financial officer and principal accounting officer.

These new employment agreements provide for substantially the same compensation as each officer’s respective prior offer letters. As previously disclosed in our proxy statement/prospectus dated September 29, 2023 and filed with the Securities and Exchange Commission, or SEC, pursuant to Rule 424(b), we entered into the new employment agreements with each of Mr. Agarwal and Dr. Aiyar, along with our other executive officers, to provide enhanced severance pay and benefits in the event the executive’s employment is terminated by us without cause or the executive resigns for good reason, in each case, within the change in control period, as defined in such new employment agreements.

Under Dr. Aiyar’s new employment agreement, he has an initial annual base salary of $498,487, an initial target bonus opportunity equal to 45% of his base salary and continues to remain eligible for equity grants under our equity incentive plans, and continues to be eligible to participate in our employee benefit plans generally. Under Mr. Agarwal’s new employment agreement, he has an initial annual base salary of $426,483, an initial target bonus opportunity equal to 35% of his base salary and continues to remain eligible for equity grants under our equity incentive plans, and continues to be eligible to participate in our employee benefit plans generally.

The new employment agreements provide that in the event the executive is terminated without “cause” or he resigns for “good reason” (as such terms are defined therein), in each case, outside of the change in control period (which runs from the three months prior to 12 months following a change in control, as “change in control” is defined in the therein), in each cash subject to signing and complying with a separation agreement and release, then the executive will be entitled to the following severance benefits: for Dr. Aiyar, (i) 12 months of his then-current base, plus (ii) a pro rata target bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year, and (iii) up to 12 months of COBRA health coverage; and for Mr. Agarwal, (i) nine months of his then-current base, plus (ii) a pro rata target bonus for the year of termination, without regard to whether the metrics have been established or achieved for such year, and (iii) up to nine months of COBRA health coverage.

The new employment agreements provide enhanced severance pay and benefits in the event the executive’s employment is terminated by us without cause or the executive resigns for good reason, in each case, within the change in control period. Such enhanced severance pay and benefits consist of (i) a lump sum cash payment equal to the sum of (A) 12 months (18 months for Dr. Aiyar) of the executive’s then-current base salary (or the base salary in effect immediately prior to the change in control, if higher) plus (B) 1.0 times (1.5 times for Dr. Aiyar) the executive’s target annual bonus for the then current year, without regard to whether the metrics have been established or achieved for such year, (ii) up to 12 months (18 months for Dr. Aiyar) of COBRA health coverage, and (iii) accelerated vesting of the then-outstanding and unvested portion of the executive’s stock options and other stock-based awards that are subject solely to time-based vesting (and, for Dr. Aiyar, any stock options and other stock-based awards that were granted to him prior to the effective date of his new employment agreement and that are subject to performance-based vesting). The severance pay and benefits described in this paragraph are subject to the executive’s delivery of and compliance with a fully effective release of claims.

The payments and benefits under the new employment agreements in connection with a change in control may not be eligible for federal income tax deduction for us pursuant to Section 280G of the Internal Revenue Code of 1986, as amended, or the Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to the executive in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.

The foregoing description of the new employment agreements does not purport to be complete and is qualified in its entirety by the full text of such agreements, which are filed hereto as Exhibit 10.1 and Exhibit 10.2 and incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

10.1+		Employment Agreement, dated as of November 10, 2023, by and between Korro Bio, Inc. and Ram Aiyar, Ph.D.

10.2+		Employment Agreement, dated as of November 8, 2023, by and between Korro Bio, Inc. and Vineet Agarwal

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

+	Indicates management contract or compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-10.1 2 d416540dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Ram Aiyar, Ph.D. (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated October 13, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Employment.

(a) Term. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”). Korro Bio Ops, Inc. initially will be the Executive’s employer of record and will maintain and distribute employment-related records. In the interest of clarity, any intercompany transfer from Korro Bio Ops, Inc. to Parent or another entity within the definition of “Company” shall not be deemed a termination of the employment relationship unless otherwise specified at the time of the transfer. The Executive’s employment with the Company shall continue to be “at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. The duties of the Company set forth in this Agreement may be discharged by any entity within the definition of “Company” set forth above.

(b) Position and Duties. The Executive shall serve as the President and Chief Executive Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors of Parent (the “Board”). The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.

(c) Location. The Executive shall work in the Company’s offices, currently located in Cambridge, Massachusetts, provided that the Executive may be required to travel for business from time to time, consistent with the Company’s business needs.

2. Compensation and Related Matters.

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $498,487 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executives.

(b) Annual Bonus. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive bonus shall be 45 percent of the Executive’s Base Salary. The Executive’s target annual incentive bonus may be reviewed by the Board or the Compensation Committee from time to time in its discretion. The target annual incentive bonus in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive bonus, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in an applicable incentive compensation plan, the Executive must be employed by the Company on the date such incentive bonus is paid in order to earn or receive any annual incentive bonus.

(c) Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executives.

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

(e) Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.

(f) Equity. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the Company’s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below).

3. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a) Death. The Executive’s employment hereunder shall terminate upon death.

(b) Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(c) Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:

(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive’s duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by the Board; (B) dishonesty to the Board with respect to any material matter; or (C) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes;

(ii) the commission by the Executive of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

(iii) any misconduct by the Executive, regardless of whether or not in the course of the Executive’s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position;

(iv) continued non-performance by the Executive of the Executive’s duties hereunder (other than by reason of the Executive’s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the Board;

(v) a material breach by the Executive of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement (as defined below);

(vi) a material violation by the Executive of any of the Company’s written employment policies; or

(vii) the Executive’s failure to reasonably cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.

(d) Termination by the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e) Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive’s consent (each, a “Good Reason Condition”):

(i) a material diminution in the Executive’s responsibilities, authority or duties or a change in the Executive’s title;

(ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions of the same percentage based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company;

(iii) a material change in the geographic location at which the Executive is regularly required to provide services to the Company (excluding any approved remote work arrangement or business travel), such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive’s principal residence as of such change; or

(iv) a material breach of this Agreement by the Company.

The “Good Reason Process” consists of the following steps:

(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 90 days of the first occurrence of such condition;

(iii) the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;

(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

(v) the Executive terminates employment within 90 days after the end of the Cure Period.

If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

4. Matters related to Termination.

(a) Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(b) Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.

(c) Accrued Obligations. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the Date of Termination and, if applicable, any accrued but unused vacation through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Obligations”).

(d) Resignation of All Other Positions. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive’s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.

5. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period. If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates employment for Good Reason as provided in Section 3(e), in each case outside of the Change in Control Period, then, in addition to the Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and, in the Company’s sole discretion, a one-year post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations (as determined by the Board in good faith), all payments of the Severance Amount shall immediately cease (the “Separation Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven (7) calendar day or seven (7) business day revocation period, as applicable:

(a) the Company shall pay the Executive an amount equal to the sum of (i) 12 months of the Executive’s Base Salary plus (ii) the Executive’s Target Bonus for the year in which the Date of Termination occurs, without regard to whether the metrics have been established or achieved for such year, with such bonus amount to be prorated to reflect the period during such year that the Executive was employed by the Company prior to the Date of Termination (the “Severance Amount”); and

(b) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments, if to the Executive, shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

6. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive’s employment is terminated either (A) by the Company without Cause as provided in Section 3(d), or (B) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within the Change in Control Period. These provisions shall terminate and be of no further force or effect after the Change in Control Period. For the avoidance of doubt, (i) in no event will the Executive be entitled to severance benefits under both Section 5 and Section 6 of this Agreement, and (ii) if the Company has commenced providing severance pay and benefits to the Executive under Section 5 prior to the date that the Executive becomes eligible to receive severance pay and benefits under this Section 6, the severance pay and benefits previously provided to the Executive under Section 5 shall reduce the severance pay and benefits to be provided under this Section 6.

(a) If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs within the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement and shall not include any affirmative obligations of the Executive to the Company beyond the Executive’s existing obligations to the Company immediately preceding the Date of Termination (the “Release”) by the Executive and the Release becoming fully effective, all within the time frame set forth in the Release but in no event more than 60 days after the Date of Termination:

(i) the Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A) 18 months of the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) 150% of the Executive’s Target Bonus for the year in which the Date of Termination occurs, without regard to whether the metrics have been established or achieved for such year (the “Change in Control Payment”); and

(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all stock options and other stock-based awards held by the Executive that (i) are subject solely to time-based vesting or (ii) were granted to the Executive prior to the Effective Date of this Agreement and are subject to performance-based vesting (the “Equity Awards”) shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i) the Date of Termination or the date of the Change in Control, as applicable or (ii) the effective date of the Release (the “Accelerated Vesting Date”), provided that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive’s Equity Awards that would otherwise terminate or be forfeited on the Date of Termination will be delayed until the earlier of (A) the date on which both a Change in Control and the effective date of the Release has occurred (at which time acceleration will occur), or (B) the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive’s Equity Awards will terminate or be forfeited). Notwithstanding the foregoing, no additional vesting of the Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and

(iii) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 18 month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments, if to the Executive, shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination or, if later, the Change in Control; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b) Additional Limitation.

(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).

(ii) For purposes of this Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.

(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(i) “Change in Control” shall mean a “Sale Event” as defined in the Company’s 2023 Stock Option and Incentive Plan, as amended from time to time.

(ii) “Change in Control Period” shall mean the period beginning on the date that is three (3) months immediately before the date of the first event constituting a Change in Control and ending on the 12 month anniversary of the first event constituting a Change in Control.

7. Section 409A.

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

8. Continuing Obligations.

(a) Restrictive Covenants Agreement. As a condition of the Executive’s continued employment, the Executive shall enter into the Employee Proprietary Information and Inventions Assignment Agreement attached hereto as Exhibit A (the “Restrictive Covenants Agreement”). For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” For the avoidance of doubt, all restrictive covenants obligations are supplemental to one another, and in the event of any conflict between restrictive covenants obligations, the most restrictive provision that is enforceable shall govern.

(b) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.

(c) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(c).

(d) Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.

9. Indemnification. The indemnification agreement between the Company and the Executive (the “Indemnification Agreement”) shall remain in full force and effect.

10. Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

11. Waiver of Jury Trial. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.

12. Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Equity Documents, the Continuing Obligations and the Indemnification Agreement remain in full force and effect.

13. Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

14. Assignment; Successors and Assigns. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided, further that if the Executive remains employed or becomes employed by the Company,

the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails to make such designation).

15. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

16. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

17. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

18. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to the Company email address of the Executive or, in the case of Company, the email address of the Chair of the Board, with confirmation of receipt.

19. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

20. Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except that the Executive shall have no rights to any severance benefits under any

Company severance pay plan, offer letter or otherwise. Notwithstanding anything to the contrary in this Agreement, all severance pay and benefits provided to the Executive pursuant to Section 5 or Section 6 of this Agreement (as applicable) shall be reduced and/or offset by any amounts or benefits paid to the Executive to satisfy the federal Worker Adjustment and Retraining Notification (WARN) Act, 29 U.S.C. § 2101 et seq., as amended, and any applicable state plant or facility closing or mass layoff law (whether as damages, as payment of salary or other wages during an applicable notice period or otherwise). In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.

21. Governing Law. This is a Delaware contract and shall be construed under and be governed in all respects by the laws of the State of Delaware, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the Third Circuit.

22. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

23. Clawback Acknowledgement. The Executive acknowledges that the Executive may become subject to the Korro Bio, Inc. Compensation Recovery Policy adopted pursuant to Rule 10D-1 promulgated under the Securities Exchange Act of 1934 and Nasdaq Rule 5608, or any successor rule (the “Clawback Policy”). The Executive understands that if the Executive is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Executive pursuant to such means as the Company and/or the Board may elect. The Executive agrees that the Executive shall take all required action to enable such recovery. The Executive understands that such recovery may be sought and occur after the Executive’s employment or service with the Company terminates. The Executive further agrees that the Executive is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Executive hereby irrevocably agrees to forego such indemnification. The Executive acknowledges and agrees that the Executive has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Executive shall not, whether alone or in combination with any other action, event or condition, be deemed (i) a Good Reason Condition or serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to the Executive, or (ii) to constitute a breach of a contract or other arrangement to which the Executive is a party. This Section 23 is a material term of this Agreement.

[Signature page follows]

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.


KORRO BIO, INC. on behalf of itself and its subsidiaries,

By:		/s/ Nessan Bermingham
Title:		Board Chairman
Date:		November 10, 2023

EXECUTIVE

/s/ Ram Aiyar

Ram Aiyar, Ph.D.

Date: November 8, 2023

Exhibit A

Restrictive Covenants Agreement

EX-10.2 3 d416540dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Vineet Agarwal (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 12, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

1. Employment.

(b) Position and Duties. The Executive shall serve as the Chief Financial Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer (the “CEO”) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of Parent (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.

(c) Location. The Executive shall work remotely from the Executive’s home office, provided that the Executive may be required to travel regularly to the Company’s offices, currently located in Cambridge, Massachusetts, as well as elsewhere from time to time, consistent with the Company’s business needs.

2. Compensation and Related Matters.

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $426,483 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executives.

(b) Annual Bonus. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive bonus shall be 35 percent of the Executive’s Base Salary. The Executive’s target annual incentive bonus may be reviewed by the Board or the Compensation Committee from time to time in its discretion. The target annual incentive bonus in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive bonus, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in an applicable incentive compensation plan, the Executive must be employed by the Company on the date such incentive bonus is paid in order to earn or receive any annual incentive bonus.

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

(e) Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.

3. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a) Death. The Executive’s employment hereunder shall terminate upon death.

(c) Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:

(i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive’s duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by the Board or CEO; (B) dishonesty to the Board or CEO with respect to any material matter; or (C) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes;

(ii) the commission by the Executive of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

(v) a material breach by the Executive of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement (as defined below);

(vi) a material violation by the Executive of any of the Company’s written employment policies; or

(i) a material diminution in the Executive’s responsibilities, authority or duties;

(ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company;

(iv) a material breach of this Agreement by the Company.

The “Good Reason Process” consists of the following steps:

(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 90 days of the first occurrence of such condition;

(iii) the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;

(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

(v) the Executive terminates employment within 90 days after the end of the Cure Period.

If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

4. Matters related to Termination.

(a) the Company shall pay the Executive an amount equal to the sum of (i) nine (9) months of the Executive’s Base Salary plus (ii) the Executive’s Target Bonus for the year in which the Date of Termination occurs, without regard to whether the metrics have been established or achieved for such year, with such bonus amount to be prorated to reflect the period during such year that the Executive was employed by the Company prior to the Date of Termination (the “Severance Amount”); and

(b) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the nine (9) month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments, if to the Executive, shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over nine (9) months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

(i) the Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A) 12 months of the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) 100% of the Executive’s Target Bonus for the year in which the Date of Termination occurs, without regard to whether the metrics have been established or achieved for such year (the “Change in Control Payment”); and

(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the “Time-Based Equity Awards”) shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i) the Date of Termination or the date of the Change in Control, as applicable or (ii) the effective date of the Release (the “Accelerated Vesting Date”), provided that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive’s Time-Based Equity Awards that would otherwise terminate or be forfeited on the Date of Termination will be delayed until the earlier of (A) the date on which both a Change in Control and the effective date of the Release has occurred (at which time acceleration will occur), or (B) the date that the Release can no longer become fully effective (at which time the unvested portion of the Executive’s Time-Based Equity Awards will terminate or be forfeited). Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and

(iii) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments, if to the Executive, shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

(b) Additional Limitation.

with Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).

(i) “Change in Control” shall mean a “Sale Event” as defined in the Company’s 2023 Stock Option and Incentive Plan, as amended from time to time.

7. Section 409A.

8. Continuing Obligations.

9. Indemnification. The indemnification agreement between the Company and the Executive (the “Indemnification Agreement”) shall remain in full force and effect.

18. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the CEO. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to the Company email address of the Executive or, in the case of Company, the Company email address of the CEO, with confirmation of receipt.

19. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

[Signature page follows]

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.


KORRO BIO, INC. on behalf of itself and its subsidiaries,

By:		/s/ Ram Aiyar
Title:		Chief Executive Officer
Date:		November 8, 2023

EXECUTIVE

/s/ Vineet Agarwal

Vineet Agarwal

Date: November 3, 2023

Exhibit A

Restrictive Covenants Agreement

EX-101.SCH 4 krro-20231108.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 krro-20231108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 krro-20231108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Nov. 08, 2023
Cover [Abstract]
Security Exchange Name	NASDAQ
Amendment Flag	false
Entity Central Index Key	0001703647
Document Type	8-K
Document Period End Date	Nov. 08, 2023
Entity Registrant Name	Korro Bio, Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-39062
Entity Tax Identification Number	47-2324450
Entity Address, Address Line One	One Kendall Square
Entity Address, Address Line Two	Building 600-700
Entity Address, Address Line Three	Suite 6-401
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	(617)
Local Phone Number	468-1999
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common stock, par value $0.001 per share
Trading Symbol	KRRO
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

XML 8 d416540d8k_htm.xml IDEA: XBRL DOCUMENT 0001703647 2023-11-08 2023-11-08 NASDAQ false 0001703647 8-K 2023-11-08 Korro Bio, Inc. DE 001-39062 47-2324450 One Kendall Square Building 600-700 Suite 6-401 Cambridge MA 02139 (617) 468-1999 false false false false Common stock, par value $0.001 per share KRRO true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #Z@VY799!YDAD! #/ M P $P @ 'S$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" ]% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d416540d8k.htm krro-20231108.xsd krro-20231108_lab.xml krro-20231108_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d416540d8k.htm": { "nsprefix": "krro", "nsuri": "http://frequencytx.com/20231108", "dts": { "inline": { "local": [ "d416540d8k.htm" ] }, "schema": { "local": [ "krro-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "krro-20231108_lab.xml" ] }, "presentationLink": { "local": [ "krro-20231108_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2022": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "report": { "R1": { "role": "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-08_to_2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d416540d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-08_to_2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d416540d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine3", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://frequencytx.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-23-277147-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-277147-xbrl.zip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�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end